Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no
universally adopted guidelines or standardized procedures for evaluating agent validity …

Clonogenic assays evaluate the ability of single cells to proliferate and form colonies. This
process approximates the regrowth and recurrence of tumors after treatment with radiation …

External beam radiotherapy is indicated in approximately 50-60% of human cancer patients.
The prescribed dose of ionizing radiation that can be delivered to a tumor is determined by …

Over the past century, technologic advances have promoted the evolution of radiation
therapy into a precise treatment modality allowing for the maximal administration of dose to …

Predictive biomarkers that allow rational selection of treatments for individual patients have
played a central role in precision oncology. While such biomarkers have transformed …

The combination of molecular-targeted agents with irradiation is a highly promising avenue
for cancer research and patient care. Molecular-targeted agents are in themselves not …

Recent advances in understanding the tumor's biology in line with a constantly growing
number of innovative technologies have prompted characterization of patients' individual …

Chemoradiation is the standard therapy for the majority of inoperable, locally advanced
cancers. Although there is a need to improve chemoradiation efficacy, normal-tissue toxicity …

Effective radiotherapy for cancer has relied on the promise of maximally eradicating tumor
cells while minimally killing normal cells. Technological advancement has provided state-of …

Chemoradiation, either alone or in combination with surgery or induction chemotherapy, is
the current standard of care for most locally advanced solid tumors. Though chemoradiation …